NEW YORK, October 12, 2016 /PRNewswire/ --
Stock-Callers.com has initiated research reports on the following Medical Laboratories and Research equities: Quest Diagnostics Inc. (NYSE: DGX), Alere Inc. (NYSE: ALR), Organovo Holdings Inc. (NASDAQ: ONVO), and DexCom Inc. (NASDAQ: DXCM). These companies belong to the Healthcare sector which was lower in pre-market trading on Tuesday, October 11, 2016. Today's research reports on the aforementioned stocks are downloadable for free upon registration at:
Madison, New Jersey headquartered Quest Diagnostics Inc.'s stock finished Tuesday's session at $83.31, which was a decline of 1.79%. A total volume of 986,206 shares was traded. Over the last month and the previous three months, the Company's shares have advanced 1.75% and 0.73%, respectively. Additionally, the stock has gained 19.57% since the start of this year. Shares of the Company are trading above their 200-day moving average by 10.65%. Moreover, shares of Quest Diagnostics, which provides diagnostic testing information and services in the US and internationally, have a Relative Strength Index (RSI) of 45.68.
On October 6th, 2016, Quest Diagnostics announced that it will report Q3 2016 results on October 20th before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. ET on that day. Visit us today and access our complete research report on DGX at:
Shares in Waltham, Massachusetts headquartered Alere Inc. ended yesterday's session 1.65% lower at $42.87 with a total trading volume of 556,080 shares. The stock has gained 8.89% in the previous three months and 9.67% on an YTD basis. The Company's shares are trading 4.15% above their 50-day moving average. Moreover, shares of Alere, which provides professional diagnostic products and services for infectious and cardiometabolic disease, and toxicology in the US, Europe, and internationally, have an RSI of 50.57.
On September 6th, 2016, Alere reported that revenue for Q2 2016 was $611 million, a 2% decrease compared to $623 million in the prior year period. Net income (loss) from continuing operations during Q2 2016 was $(35) million, or $(0.46) per basic and diluted share, compared to $15 million, or $0.11 per basic and diluted share, in Q2 2015.
On September 29th, 2016, research firm CanaccordGenuity reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $56 a share to $53 a share. The complimentary report on ALR can be downloaded at:
On Tuesday, San Diego, California headquartered Organovo Holdings Inc.'s stock rose 3.15%, to close the day at $3.93. A total volume of 1.31 million shares was traded, which was above their three months average volume of 970,950 shares. The Company's shares have advanced 3.42% in the previous three months and 57.83% on an YTD basis. The stock is trading 29.88% above its 200-day moving average. Additionally, shares of Organovo Holdings, which focuses on developing and commercializing functional human tissues that could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs, have an RSI of 48.07.
On October 11th, 2016, Organovo Holdings reported preliminary unaudited revenue and net cash utilization results for Q2 FY17 and updated its FY17. The company expects to release full Q2 FY17 results on November 3rd, 2016. Organovo's preliminary Q2 FY17 total revenue was approximately $1.4 million, consisting largely of product and service revenue, this result reflects a 357% increase in total revenue versus the comparable period of FY16. The company's preliminary cash and cash equivalents balance was approximately $51.7 million as of the end of Q2 FY17, which compares to $53.5 million for Q1 FY17. The company updated its FY17 outlook and it now expects total revenue of between $4.5 million and $6.2 million. FY16 total revenue was $1.5 million. Net cash utilization was between $31.0 million and $34.0 million. Register for free on Stock-Callers.com and access the latest research report on ONVO at:
Shares in San Diego, California headquartered DexCom Inc. ended the day 2.42% lower at $81.89. A total volume of 646,469 shares was traded. The stock has gained 2.62% in the previous three months. The Company's shares are trading above their 200-day moving average by 8.94%. Furthermore, shares of DexCom, which focuses on the design, development, and commercialization of continuous glucose monitoring systems in the US and internationally, have an RSI of 28.18.
On September 7th, 2016, DexCom announced that Germany's Federal Joint Committee will provide reimbursement for Dexcom's Continuous Glucose Monitoring (CGM) Systems for patients with insulin-dependent type 1 and type 2 diabetes. The policy change was approved by Germany's Ministry of Health and has now been initiated. The new reimbursement policy in Germany only covers technologies that provide alarms and alerts about glucose levels - including the DexCom CGM System. Get free access to your research report on DXCM at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA